Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective

Qingyang Xu1 MIT Laboratory for Financial Engineering, Cambridge, MA, USA;2 MIT Operations Research Center, Cambridge, MA, USAView further author information

Joonhyuk Cho1 MIT Laboratory for Financial Engineering, Cambridge, MA, USA;3 MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USAView further author information

Zied Ben Chaouch1 MIT Laboratory for Financial Engineering, Cambridge, MA, USA;3 MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USAView further author information

Andrew W. Lo1 MIT Laboratory for Financial Engineering, Cambridge, MA, USA;2 MIT Operations Research Center, Cambridge, MA, USA;3 MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USA;4 MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA;5 MIT Sloan School of Management, Cambridge, MA, USA, and;6 Sante Fe Institute, Santa Fe, NM, USACorrespondence[email protected]
View further author information

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date